Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates

@article{Smith2018AttenuationAE,
  title={Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates},
  author={D. Smith and S. Johnston and Ashley E Piper and Miriam A. Botto and G. Donnelly and J. Shamblin and C. Albari{\~n}o and L. Hensley and C. Schmaljohn and S. Nichol and B. Bird},
  journal={PLoS Neglected Tropical Diseases},
  year={2018},
  volume={12}
}
  • D. Smith, S. Johnston, +8 authors B. Bird
  • Published 2018
  • Biology, Medicine
  • PLoS Neglected Tropical Diseases
    • Rift Valley fever virus (RVFV) is an important mosquito-borne veterinary and human pathogen that has caused large outbreaks of severe disease throughout Africa and the Arabian Peninsula. Currently, no licensed vaccine or therapeutics exists to treat this potentially deadly disease. The explosive nature of RVFV outbreaks and the severe consequences of its accidental or intentional introduction into RVFV-free areas provide the impetus for the development of novel vaccine candidates for use in… CONTINUE READING
    View PDF
    9 Citations
    Background Citations
    3
    Methods Citations
    1
    9 Citations
    Citation Type

    Citation Type

    Candidate vaccines for human Rift Valley fever
    • T. Ikegami
    • Biology, Medicine
    • Expert opinion on biological therapy
    • 2019
    • 2
    Rift Valley Fever: Important Considerations for Risk Mitigation and Future Outbreaks
    • 1
    • PDF
    Rift Valley Fever – epidemiological update and risk of introduction into Europe
    • 2
    • PDF
    The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review
    • 12
    • PDF
    Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile
    Reverse genetics approaches for the development of bunyavirus vaccines.
    Efficacy of Montanide (IMS 3015) as an adjuvant for an inactivated Rift Valley fever (RVF) vaccine in sheep.
    Virion-associated spermidine transmits with Rift Valley fever virus particles to maintain infectivity
    • 1
    • PDF
    p38γ Activation and BGP (Biliary Glycoprotein) Induction in Primates at Risk for Inflammatory Bowel Disease and Colorectal Cancer—A Comparative Study with Humans
    • PDF

    References

    SHOWING 1-10 OF 67 REFERENCES
    Rift Valley Fever Virus Lacking the NSs and NSm Genes Is Highly Attenuated, Confers Protective Immunity from Virulent Virus Challenge, and Allows for Differential Identification of Infected and Vaccinated Animals
    • 160
    • PDF
    Rift Valley Fever Virus Vaccine Lacking the NSs and NSm Genes Is Safe, Nonteratogenic, and Confers Protection from Viremia, Pyrexia, and Abortion following Challenge in Adult and Pregnant Sheep
    • 94
    • PDF
    Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR
    • 19
    Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.
    • 22
    • PDF
    Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys.
    • 59
    Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease.
    • 103
    The pathogenesis of Rift Valley fever virus in the mouse model.
    • 90
    Aerosolized Rift Valley Fever Virus Causes Fatal Encephalitis in African Green Monkeys and Common Marmosets
    • 41
    • PDF
    Rescue of Infectious Rift Valley Fever Virus Entirely from cDNA, Analysis of Virus Lacking the NSs Gene, and Expression of a Foreign Gene
    • 192
    • PDF
    Rift Valley Fever Virus Encephalitis Is Associated with an Ineffective Systemic Immune Response and Activated T Cell Infiltration into the CNS in an Immunocompetent Mouse Model
    • 32
    • PDF